GLOBAL SWEDISH SITE FINANCIALS FINANCIAL REPORTS PRESENTATIONS THE SHARE SHAREHOLDERS ANALYST COVERAGE CORPORATE GOVERNANCE CALENDAR Q&A DEFINITIONS SHAREHOLDERS On September 30, 2021, BONESUPPORT HOLDING AB had 8,442 shareholders. The largest shareholders are presented below, in number of shares and part of total number of shares: Ten largest shareholders Avanza 6 979 722 10,7% HealthCap V LP 6 602 360 10,1% Swedbank Robur Fonder 4 144 426 6,3% State Street Bank and Trust 3 852 713 5,9% Stiftelsen Industrifonden 3 787 806 5,8% Tredje AP-fonden 3 691 969 5,6% Fjärde AP-Fonden 3 142 458 4,8% Lancelot Avalon 2 250 000 3,4% Svenskt Näringsliv 1 670 000 2,6% Futur Pension 1 357 824 2,1% ©BONESUPPORT AB 2021. ALL RIGHTS RESERVED. CERAMENT and BONESUPPORT are registered Trademarks of BONESUPPORT AB. HOME CONTACT US PRIVACY POLICY COOKIE POLICY This website uses cookies By using our website you consent to all cookies in accordance with our Cookie Policy. Read more ACCEPT ALL DECLINE ALL POWERED BY COOKIE-SCRIPT

GLOBAL SWEDISH SITE PIPELINE CURRENT TECHNOLOGY CERTIFY CLINICAL TRIAL CURRENT TECHNOLOGY CERAMENT is a synthetic injectable and flowable bone void filler that consists of a powder component: 40% hydroxyapatite (HA), 60% calcium sulfate (CaS), and a liquid component, which are mixed to form a paste. The proprietary combination of hydroxyapatite and calcium sulfate is designed to enable CERAMENT to resorb at the same rate that bone forms. Calcium sulfate acts as a resorbable carrier for hydroxyapatite. Hydroxyapatite has a slow resorption rate and high osteoconductivity promoting bone ingrowth and gives long term structural support to the newly formed bone. CERAMENT G and CERAMENT V have been developed for situations where there is a risk that the bone healing process may be disturbed by the colonization of microbial organisms. The addition of the antibiotics gentamicin in CERAMENT G and vancomycin in CERAMENT V, inhibit colonization by gentamicin or vancomycin-sensitive microorganisms, in order to protect bone healing. CERAMENT may be used instead of autograft or allograft, and the characteristics of CERAMENT G and V mean that surgeons can manage bone defects in a more patient-friendly single-stage procedure. CERAMENT G has proven clinical outcomes, with one of the lowest (re)fracture and (re)infection rates of any synthetic bone substitute on the market. Moving to a single-stage from a multi-stage surgical protocol also frees healthcare resources to meet other needs, paving the way for a more cost-effective strategy for hospitals. These attractive properties have resulted in more than 50,000 patients having been treated with CERAMENT and over 160 publications and abstracts, confirming safety and efficacy. REFERENCES ©BONESUPPORT AB 2021. ALL RIGHTS RESERVED. CERAMENT and BONESUPPORT are registered Trademarks of BONESUPPORT AB. HOME CONTACT US PRIVACY POLICY COOKIE POLICY This website uses cookies By using our website you consent to all cookies in accordance with our Cookie Policy. Read more ACCEPT ALL DECLINE ALL POWERED BY COOKIE-SCRIPT